VS-7375, a potential best-in-class oral KRAS G12D (ON ... in multiple NRAS- and BRAF-driven tumor models corresponding with nearly complete shutdown of RAS/MAPK pathway signaling BOSTON, March ...

Each tumor specimen was screened for mutations in EGFR exons 18–21 and KRAS exon 2, and mutation status was then compared with sensitivity to the two drugs.